Top Page
Acusensus Ltd
(Sydney:ACE)
Acusensus Ltd (ACE) vs. iShares MSCI Australia ETF (EWA)
Acusensus Ltd Business Overview & Revenue Model
Acusensus Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 59.35M | 59.35M | 49.63M | 42.00M | 28.65M | 6.27M |
| Gross Profit | 26.57M | 26.57M | 22.58M | 4.61M | 3.21M | -1.18M |
| EBITDA | -366.00K | 3.89M | 5.33M | 5.35M | 4.38M | -2.97M |
| Net Income | -2.62M | -2.62M | -1.52M | 55.37K | 1.43M | -3.65M |
Balance Sheet | ||||||
| Total Assets | 73.53M | 73.53M | 48.69M | 48.46M | 26.16M | 19.57M |
| Cash, Cash Equivalents and Short-Term Investments | 21.45M | 21.45M | 19.34M | 24.80M | 8.61M | 12.33M |
| Total Debt | 7.93M | 7.93M | 2.19M | 2.19M | 2.33M | 977.62K |
| Total Liabilities | 26.73M | 26.73M | 12.77M | 12.54M | 9.40M | 4.50M |
| Stockholders Equity | 46.79M | 46.79M | 35.92M | 35.92M | 16.76M | 15.07M |
Cash Flow | ||||||
| Free Cash Flow | -4.99M | -7.23M | -3.94M | -1.12M | -2.28M | -3.85M |
| Operating Cash Flow | 8.27M | 8.27M | 3.58M | 4.26M | 4.97M | -1.00M |
| Investing Cash Flow | -13.71M | -13.71M | -7.52M | -17.37M | -7.24M | -3.17M |
| Financing Cash Flow | 9.25M | 9.25M | -1.47M | 17.34M | -1.44M | 15.38M |
Acusensus Ltd Technical Analysis
Acusensus Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
49 Neutral | AU$261.38M | -84.29 | -6.34% | ― | 19.60% | -59.17% | |
48 Neutral | AU$34.81M | -1.23 | -64.51% | 4.99% | -38.38% | -275.50% | |
44 Neutral | AU$7.32M | -2.63 | ― | ― | 13.07% | 68.60% | |
42 Neutral | AU$10.61M | -1.22 | -54.62% | ― | -22.47% | 39.26% | |
42 Neutral | AU$5.40M | -3.47 | -23.31% | ― | 2.15% | -900.00% |
Acusensus Ltd Corporate Events
Acusensus Ltd has applied to the Australian Securities Exchange for quotation of 160,000 additional fully paid ordinary shares under the ticker ACE, to be issued on 7 January 2026. The small equity issuance, arising from the exercise or conversion of existing options or convertible securities, modestly increases the company’s quoted share capital and reflects ongoing utilisation of its equity-based instruments by holders.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Ltd has issued a total of 36,483 unquoted performance rights (ASX code ACEAAA) under its employee incentive scheme, with 28,524 rights dated 8 December 2025 and 7,959 rights dated 20 November 2025, none of which are intended to be quoted on the ASX. The move reflects the company’s ongoing use of equity-based incentives to remunerate and retain staff and align employee interests with shareholder value, without altering its quoted share capital.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Limited has issued 377,352 new fully paid ordinary shares following the exercise or conversion of previously unquoted equity securities, effective 2 December 2025. The issuance of these additional shares modestly expands the company’s share capital base and reflects the conversion of unquoted options or other convertible instruments, which may indicate employee or stakeholder incentives being realised and a further alignment of interests between management, staff and shareholders.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Limited has reported the lapse of 380,275 performance rights, which have ceased due to the relevant vesting conditions not being met or no longer being capable of being satisfied as at 31 December 2025. The cessation of these rights modestly reduces the company’s pool of potential equity-based remuneration and may slightly lessen prospective dilution for existing shareholders, while signalling that certain performance or service hurdles tied to these rights were not achieved within the prescribed timeframe.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Limited has completed the issue of 20 million fully paid ordinary shares at $1.50 per share under a previously announced non-underwritten placement, raising $30 million in new equity. The company confirmed the placement was conducted without a prospectus under the Corporations Act disclosure exemptions and stated it remains compliant with its continuous and financial reporting obligations, with no excluded information requiring disclosure, positioning the new shares for secondary trading and reinforcing the company’s capital base for ongoing operations and growth initiatives.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Ltd has applied to the ASX for quotation of 20 million new ordinary fully paid shares under the code ACE, with an issue date of 22 December 2025. The move increases the company’s quoted securities on the market, potentially expanding its free float and liquidity, and may form part of previously flagged capital or transactional activity, though no further operational or strategic details are disclosed in the filing.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Ltd has announced a placement of new fully paid ordinary shares to professional and sophisticated investors, as well as certain existing shareholders. This move aims to raise equity for the company, potentially impacting its financial operations and market positioning. The presentation highlights that the investment carries risks and is not accompanied by financial advice, emphasizing the need for investors to conduct their own due diligence.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Ltd has announced a proposed issue of 20 million fully paid ordinary securities, scheduled for December 22, 2025. This move is part of a placement or other type of issue, which could potentially impact the company’s financial positioning and market operations by increasing its capital base, thereby enhancing its ability to invest in growth opportunities and strengthen its market presence.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Limited has successfully completed a $30 million placement of 20 million shares at $1.50 each, supported by existing and new professional investors. The funds will be used for business development, contract mobilization, product innovation, and other operational costs, enhancing the company’s growth strategy and market liquidity.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Limited has requested a trading halt on its securities on the ASX as it prepares to announce a significant capital raising initiative. This move is expected to impact the company’s financial positioning, potentially enhancing its market capabilities and stakeholder value once the capital raising is completed.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Ltd has announced the quotation of 377,352 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code ACE, effective December 3, 2025. This move is part of an employee incentive scheme and reflects the company’s ongoing efforts to enhance its market presence and operational capabilities.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Ltd has announced the issuance of 197,302 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code ACE. This move is part of the company’s strategy to enhance its market presence and operational capabilities, potentially impacting its industry positioning by increasing its capital base and shareholder value.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Limited has announced a change in the director’s interest, specifically involving Alexander Jannink, who is a director, shareholder, and beneficiary of Jannink & Associates Pty Ltd. This change in interest involves unquoted performance rights and reflects the company’s ongoing governance and compliance with ASX listing rules. Such changes can impact the company’s operational transparency and investor relations, maintaining stakeholder confidence in its governance practices.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Ltd has announced the issuance of 225,275 performance rights as part of an employee incentive scheme. These unquoted securities are not intended to be listed on the ASX, reflecting the company’s strategy to enhance employee engagement and retention through equity-based incentives. This move is likely to strengthen Acusensus’s operational framework by aligning employee interests with company performance, potentially impacting its market positioning positively.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Limited announced the successful outcomes of its 2025 Annual General Meeting, with all resolutions passed. This development reflects positively on the company’s governance and strategic direction, potentially strengthening its position in the road safety technology industry and reassuring stakeholders of its commitment to innovation and safety.
The most recent analyst rating on (AU:ACE) stock is a Buy with a A$2.30 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Limited has announced an expansion of its contract with the Queensland Department of Transport and Main Roads, doubling the number of trailer-based speed enforcement units. This expansion, valued at approximately $16.6 million, will see new units deployed from November 2025 through 2026, each for an initial five-year term. The program has already demonstrated significant success, with a 92% reduction in excessive speeding detected in the first seven months, highlighting its impact on road safety and driver behavior.
The most recent analyst rating on (AU:ACE) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Limited announced that its Co-Founder and Managing Director, Alexander Jannink, will present at the Morgans Conference in Noosa, Australia. The presentation highlights Acusensus’ commitment to leveraging AI technology to enhance road safety by providing digital evidence for law enforcement. This announcement underscores the company’s ongoing efforts to strengthen its industry position and its dedication to improving road safety through innovative solutions.
The most recent analyst rating on (AU:ACE) stock is a Buy with a A$2.05 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Limited has issued its 2025 Notice of Annual General Meeting, scheduled for November 19, 2025, in Melbourne. The notice provides details on the meeting’s agenda and shareholder participation. This announcement signifies Acusensus’s ongoing commitment to transparency and shareholder engagement, potentially impacting its operational strategies and stakeholder relations.
The most recent analyst rating on (AU:ACE) stock is a Buy with a A$2.05 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Ltd has announced the application for the quotation of 745,000 ordinary fully paid securities on the Australian Securities Exchange (ASX), with the issue date set for October 17, 2025. This move is part of the company’s strategic efforts to enhance its market presence and operational capabilities, potentially impacting its industry positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:ACE) stock is a Buy with a A$2.05 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.